NEWS IN BRIEF

Sagent acquires US facility with an eye on future biosimilar products

By Staff reporter

- Last updated on GMT

(Image: Getty/Darwin Brandis)
(Image: Getty/Darwin Brandis)

Related tags: Sagent, Nichi-Iko, North carolina

Sagent purchases Xellia’s FDA-approved site in North Carolina, which has capabilities to manufacture both small molecule and biologic products.

Sagent Pharmaceuticals, part of the Nichi-Iko company, invested in a manufacturing site in North Carolina, US. Sagent did not reveal the financial terms of the transaction.

The Raleigh-based site can manufacture both small molecule and biologic products, and is US Food and Drug Administration (FDA) approved.

CEO of Sagent, Peter Kaemmerer, stated that the facility will be used to “enable production of lyophilised formulations of [its] future biosimilar product offerings.”

Additionally, the company will continue to supply Xellia Pharmaceuticals with products from the facility. Kaemmerer confirmed that existing staff members will be retained as part of the acquisition.

The site represents the first facility that Sagent, and its parent company, Nichi-Iko, will own in the US. CEO of Nichi-Iko, Yuichi Tamura, suggested that the move would strengthen its position in the US market, in terms of competitiveness and capability.

Nichi-Iko acquired Sagent​ for $736m (€652m) in 2016, and is one of the largest generic drug manufacturers in Japan, by sales. In full-year financials for 2017-2018, it posted net sales of $1.47bn.

Related news

Related products

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers

Follow us

Products

View more

Webinars